Chau K, Hennessy A, Makris A
Vascular Immunology Group, Heart Research Institute, Newtown, New South Wales, Australia.
Department of Renal Medicine, Regional Dialysis Centre, Blacktown Hospital, Blacktown, New South Wales, Australia.
J Hum Hypertens. 2017 Dec;31(12):782-786. doi: 10.1038/jhh.2017.61. Epub 2017 Aug 24.
Placental growth factor (PlGF) is an increasingly important molecule in the prediction, diagnosis and treatment of pre-eclampsia. It has pro-angiogenic effects on the feto-placental circulation and supports trophoblast growth. Mechanisms by which PlGF expression is regulated continue to be investigated. Low circulating PlGF precedes the manifestation of clinical disease in pre-eclamptic pregnancies and intrauterine growth restriction. This suggests that low PlGF is a marker of abnormal placentation, but it remains uncertain whether this is a cause or consequence. Prediction of pre-eclampsia using PlGF is promising and may assist in the targeting of resources to women at highest risk of adverse pregnancy outcomes. Promisingly, experimental animal models of pre-eclampsia have been successfully treated with supplemental PlGF. Treatment of pre-eclampsia with PlGF is a potential therapeutic option requiring further exploration. This review focuses specifically on the role of PlGF in normal and pathological placental development and in the clinical management of pre-eclampsia.
胎盘生长因子(PlGF)在子痫前期的预测、诊断和治疗中是一种日益重要的分子。它对胎儿 - 胎盘循环具有促血管生成作用,并支持滋养层生长。调节PlGF表达的机制仍在研究中。在子痫前期妊娠和胎儿宫内生长受限中,循环中PlGF水平降低先于临床疾病的表现。这表明低PlGF是胎盘形成异常的一个标志物,但它究竟是原因还是结果仍不确定。使用PlGF预测子痫前期很有前景,可能有助于将资源靶向到妊娠不良结局风险最高的女性。有希望的是,子痫前期的实验动物模型已通过补充PlGF成功治疗。用PlGF治疗子痫前期是一个需要进一步探索的潜在治疗选择。本综述特别关注PlGF在正常和病理胎盘发育以及子痫前期临床管理中的作用。